Based on a century of medical discoveries, we propose a methodology of using lifestyle interventions and proactive body temperature management protocol as prevention and cure for COVID-19 disease. We produce robust evidence to show that lifestyle interventions have a 100% “expected response rate”, with a curative power being one to three orders of magnitude larger than that of a single lifestyle factor determined by clinical trials and can deliver immediate benefits to long-term curative benefits. On basis of a large number of studies, we propose that the local blood flow along the inner surface of the respiratory track works like an anti-viral shield, which is capable of robustly prevent and terminate viral and other infections. Breathing cold temperature from 26 °C to a frigid temperature can dramatically reduce local temperatures along the track and thus cripples the protective shield by reducing local blood flow to as little as 3-10%. A proactive body temperature management protocol (PBTM or PRTPM), which comprises pre-exposure, during-exposure, and post-exposure measures, are capable of boosting innate immune functions, anti-viral defenses, and vital organ functions. We estimate that pre-exposure and during-exposure measures can reduce temperature drops along the tract by 5°C to 20 °C, and that a series of post-exposure measures can increase local blood flow rates along the track by 2 to 20 times. The proposed measures can completely restore the anti-viral shield. All kinds epidemiological data support our estimated curative power that the protocol can prevent 90% to 97% infection incidences and deaths. We show that the protocol is even more powerful than vaccine, and maintaining a reasonable local temperature along the respiratory track is a required condition for delivering and boosting vaccine’s protection.Current medical researches have excluded temperature and air as treatments in all on-going clinical trials. This misplaced priority is an inevitable result of the financial arrangement of all parties in medicine. Such financial arrangement provides too much incentive for medicalization, the key elements of which include finding revenue-making treatments, producing good data for promoting the treatments, and finding more patients for using treatments. Since lifestyle interventions and proactive body temperature management protocol cannot be studied by flawed research model and cannot be patented for monopoly, no entity has incentives to explore their extraordinary benefits. We also found that the reason of failure to contain the COVID-19 pandemic is same as failure to find cures for cancer and AIDS. Several studies imply that best solutions for cancer, AIDS and all chronic diseases are not revenue-generating medical treatments, but things that cannot sold for revenues and things that are born and carried in human genome. Based on a century of medical discoveries in disease causes, we propose for the federal government that the most cost-effective measures are finding and eliminating a large number of disease causes hidden in food production lines, family kitchens, cooking culture, personal cooking habits, home appliances, etc. This is the only way to root out causes for more than 90% chronic diseases incidences.

Biocompatible polymers have emerged as essential materials in medical 3D printing, enabling the fabrication of scaffolds, tissue constructs, drug delivery systems, and biosensors for applications in and on the human body. This review aims to provide a comprehensive overview of the current state of 3D-printable biocompatible polymers and their composites, with an emphasis on their processing methods, properties, and biomedical uses. The scope of this work includes both natural and synthetic biocompatible polymers, polymer-nanocomposite systems, and bioinks that do not require photo initiators. The relevant literature was critically examined to classify materials by type, evaluate their compatibility with major 3D printing techniques such as stereolithography, selective laser sintering, and fused deposition modeling, and assess their performance in various medical applications. Key findings highlight that reinforced polymer composites, tailored surface chemistries, and hybrid printing strategies significantly expand the range of functional, customizable, and affordable biomedical devices. This review concludes by discussing present-day applications and emerging trends, underscoring that 3D-printable biocompatible polymers are rapidly transitioning from research to clinical practice, offering transformative potential for patient-specific healthcare solutions.

[Progress in the study, treatment and cure of hematologic malignancies in children in North America]. Progress in the study, treatment and cure of hematologic malignancies in children is one of the most gratifying accounts in the entire history of cancer therapy. It is important to note that progress in treatment and cure have been the direct result of formal study of childhood cancers and the development and clinical trial of new treatments designed to improve the response and cure rate. In the experience of the Children's Cancer Study Group (CCSG), approximately half of the children with cancer which are registered have hematologic malignancies. By far the most significant of these is acute lymphoblastic leukemia (ALL), which accounts for 33% of all the cancers registered with the Group. Acute non-lymphoblastic types of leukemia have amounted to 6% of all cancers in our experience, non-Hodgkin's lymphoma for another 6% and Hodgkin's disease for approximately 5%. The cancer death rate in children under the age of fifteen years has declined very significantly in the United States since 1950.

SARS-CoV-2 is the latest worldwide pandemic declared by the World Health Organization and there is no established anti-COVID-19 drug to combat this notorious situation except some recently approved vaccines. By affecting the global public health sector, this viral infection has created a disastrous situation associated with high morbidity and mortality rates along with remarkable cases of hospitalization because of its tendency to be high infective. These challenges forced researchers and leading pharmaceutical companies to find and develop cures for this novel strain of coronavirus. Besides, plants have a proven history of being notable wellsprings of potential drugs, including antiviral, antibacterial, and anticancer therapies. As a continuation of this approach, plant-based preparations and bioactive metabolites along with a notable number of traditional medicines, bioactive phytochemicals, traditional Chinese medicines, nutraceuticals, Ayurvedic preparations, and other plant-based products are being explored as possible therapeutics against COVID-19. Moreover, the unavailability of effective medicines against COVID-19 has driven researchers and members of the pharmaceutical, herbal, and related industries to conduct extensive investigations of plant-based products, especially those that have already shown antiviral properties. Even the recent invention of several vaccines has not eliminated doubts about safety and efficacy. As a consequence, many limited, unregulated clinical trials involving conventional mono- and poly-herbal therapies are being conducted in various areas of the world. Of the many clinical trials to establish such agents as credentialed sources of anti-COVID-19 medications, only a few have reached the landmark of completion. In this review, we have highlighted and focused on plant-based anti-COVID-19 clinical trials found in several scientific and authenticated databases. The aim is to allow researchers and innovators to identify promising and prospective anti-COVID-19 agents in clinical trials (either completed or recruiting) to establish them as novel therapies to address this unwanted pandemic.

Progress in cancer management. Keynote address. Management of cancer has changed drastically since the end of World War II. From the turn of the century up to that time, surgery had been the bulwark against cancer. Now in addition, over 2000 medical oncologists and over 1000 radiologists play a large role in cancer management. The majority of these were trained within the past decade through resources provided by the National Cancer Act. Early radiotherapeutic equipment caused such toxicity that scientific articles in the 1920s and 1930s questioned the utility of radiotherapy, just as they would chemotherapy at a later date. Improvement in cancer cure rates due to surgery, modern anesthesia, blood transfusions and antibiotics for serious cancers, had plateaued at about 30%. Since the introduction of the first cobalt units and then linear accelerators into medical practice in the mid-1950s, an additional 90,000 patients a year are curable by the use of radiotherapy alone, or in combination with surgery (1980 data). The first chemotherapy was introduced in about 1950, but effective treatment with drugs in the clinic really began in the 1960s.

Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3 clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years to achieve these successes? Developing potent therapies for reducing fibrillar amyloid was key, as was selection of patients at relatively early stages of disease. Biomarkers of the target pathologies, including amyloid and tau PET, and insights from past trials were also critical to the recent successes. Moving forward, the challenge will be to develop more efficacious therapies with greater efficiency. Novel trial designs, including combination therapies and umbrella and basket protocols, will accelerate clinical development. Better diversity and inclusivity of trial participants are needed, and blood-based biomarkers may help to improve access for medically underserved groups. Incentivizing innovation in both academia and industry through public-private partnerships, collaborative mechanisms, and the creation of new career paths will be critical to build momentum in these exciting times.